Pharsight

Drugs that contain Boceprevir

1. Victrelis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43298 MERCK SHARP DOHME Peptides as NS3-serine protease inhibitors of hepatitis C virus
Dec, 2024

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119602 MERCK SHARP DOHME Administration of HCV protease inhibitors in combination with food to improve bioavailability
Mar, 2027

(2 years from now)

US7772178 MERCK SHARP DOHME Pharmaceutical formulations and methods of treatment using the same
Nov, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2016
New Patient Population(NPP) Feb 13, 2016
M(M-126) Feb 27, 2016

NCE-1 date: 14 May, 2015

Market Authorisation Date: 13 May, 2011

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...

Dosage: CAPSULE;ORAL

More Information on Dosage

VICTRELIS family patents

Family Patents